Premium
1.3‐Bis(2‐chloroethyl)‐1‐nitrosourea(BCNU), cyclophosphamide, vincristine‐ and prednisone‐(BCOP): A new therapeutic regimen for diffuse histiocytic lymphoma
Author(s) -
Durant John R.,
Loeb Virgil,
Dorfman Ronald,
Chan YickKwong
Publication year - 1975
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.2820360902
Subject(s) - medicine , vincristine , prednisone , cyclophosphamide , histiocyte , regimen , lymphoma , lomustine , gastroenterology , leukopenia , surgery , chemotherapy , pathology
Sixty‐seven evaluable patients with mixed cellular and histiocytic lymphomas, both nodular and diffuse, were treated with a combined drug regimen of BCNU, cyclophosphamide, vincristine, and prednisone administered for six monthly courses. Of 28 previously untreated patients with diffuse histiocytic lymphoma, 14 (50%) achieved a complete remission, and an additional 7 (25%) had a good partial response for an overall remission rate of 75%. Complete remissions were also obtained among the small number of mixed and nodular histiocytic lymphomas which were treated. The median survival for previously untreated patients with diffuse histiocytic lymphoma who achieved a complete remission is nearly two years and 42% (8/19) of these patients remain in their initial unmaintained remission (range 2–119 weeks). Hematologic toxicity, although acceptable, was the limiting factor. Granulocytes were more often and more severely depressed than platelets.